Achillion Pharmaceuticals

At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system.

Achillion Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Therapeutics sector. The company focuses on Biotechnology and has secured $45.0B in funding across 96 round(s). With a team of 51-100 employees, Achillion Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Achillion Pharmaceuticals, raised $50.1M. Discover more about their projects, partnerships, and impact on our platform.